FDA approved launch YUVEZZI is FDA-approved for presbyopia and has recently launched in the US, signaling a ready-to-sell product with a defined target market and initial commercialization momentum that sales teams can leverage to secure early-adopter ophthalmology practices and pharmacy partners.

Strategic manufacturing A high-profile CDMO partnership with The Ritedose Corporation for sterile BFS production supports scalable supply and reliability, enabling sales conversations around capacity, on-time fulfillment, and risk mitigation for large ophthalmic distributors and clinics.

Executive leadership New CMO appointment and experienced finance leadership indicate a strengthened go-to-market strategy and clinical/regulatory focus, presenting opportunities to engage medical affairs and payer relations teams in collaboration on adoption, guidelines, and reimbursement framing.

Direct-to-patient access DTP program with PHIL emphasizes home delivery, transparent pricing, and dedicated support, offering a compelling value proposition for patient access channels, integrated care networks, and digital health partnerships to drive utilization.

Financial momentum Recent Series B financing combined with FDA approval and US market entry creates a compelling narrative for stakeholders across investors, contract manufacturers, and distributors, supporting partnership pitches around scale, marketing investment, and channel expansion.